Is Daclatasvir compatible with breastfeeding? Do we have alternatives for Daclatasvir?

Daclatasvir

August 6, 2017 (Low Risk)

Usually used alone or in combination with sofosbuvir in the treatment of hepatitis C.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk, so that, although there is disagreement (Thompson 2016), some authors consider that treatment with Daclatasvir, alone or in combination with sofosbuvir is not contraindicated during breastfeeding (Spera 2016, LactMed 2016).


See below the information of these related products:

Alternatives

We do not have alternatives for Daclatasvir.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • داكلاتاسفير (Arabic)
  • Даклатасвир (Cyrillic)
  • 达拉他韦 (Chinese)
  • C40H50N8O6 (Molecular formula)

Drug trade names

References

  1. EMA. Daclatasvir. Ficha técnica. 2017 Full text (in our servers)
  2. EMA. Daclatasvir. Drug Summary. 2017 Full text (in our servers)
  3. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016Abstract Full text (link to original source) Full text (in our servers)
  4. Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol. 2016Abstract Full text (link to original source) Full text (in our servers)
  5. LactMed. Daclatasvir. Full Record Display. 2016 Full text (in our servers)